Supernus Pharmaceuticals Inc (SUPN)

Gross profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Gross profit (ttm)	US$ in thousands	119,761	200,657	186,315	206,743	205,614	162,132	177,317	171,308	177,659	204,692	225,169	248,395	248,020	284,019	267,992	263,335	256,308	271,796	272,821	268,911
Revenue (ttm)	US$ in thousands	605,106	619,414	641,163	674,751	673,056	651,277	618,187	585,808	560,079	545,016	551,524	536,576	506,717	465,383	418,476	402,257	392,755	408,243	409,099	403,942
Gross profit margin		19.79%	32.39%	29.06%	30.64%	30.55%	24.89%	28.68%	29.24%	31.72%	37.56%	40.83%	46.29%	48.95%	61.03%	64.04%	65.46%	65.26%	66.58%	66.69%	66.57%

December 31, 2023 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $119,761K ÷ $605,106K
= 19.79%

The gross profit margin of Supernus Pharmaceuticals Inc has been relatively consistent over the past eight quarters, ranging from 85.27% to 88.34%. The company maintains a high level of efficiency in generating profits from its sales after deducting the cost of goods sold. The trend indicates that the company has been able to effectively manage its production costs and pricing strategies to maintain healthy profit margins. Additionally, the margins have been above 85% in all quarters, indicating that Supernus Pharmaceuticals Inc has a strong ability to control manufacturing and operational costs while effectively pricing its products.